Pharmacovigilance in Clinical Trials: Protecting Patients Beyond Adverse Event Reporting

When we hear the term pharmacovigilance (PV) in clinical research, one activity often comes immediately to mind:

Adverse event reporting.

It is certainly an essential part of clinical trial safety.

But pharmacovigilance is much broader.

During clinical development, every participant contributes new information about an investigational product. A laboratory abnormality, hospitalization, unexpected clinical event, pattern across several participants or finding from another study may change what we understand about its safety.

The responsibility of pharmacovigilance is therefore not simply to collect individual adverse events.

It is to ask continuously:

What is the emerging safety profile of this investigational product, and does the evolving evidence change what we need to do to protect participants?

That distinction transforms pharmacovigilance from a reporting function into a fundamental component of clinical development.

Why Safety Surveillance Is Different During Clinical Development

When an investigational medicine first enters human trials, knowledge about its safety is necessarily incomplete.

Preclinical studies provide important information, but they cannot fully predict what will happen when a product is administered to broader human populations.

Early clinical trials may involve relatively small numbers of participants.

As development progresses:

Phase I → Phase II → Phase III → Post-Authorisation

the number and diversity of people exposed to the medicine generally increases, and the safety profile becomes progressively better characterized.

Clinical trial pharmacovigilance therefore operates in an environment of evolving knowledge.

An adverse event that initially appears isolated may later become part of a recognizable pattern.

A risk believed to be theoretical may become clinically relevant.

An expected adverse reaction may occur more frequently or severely than anticipated.

Safety surveillance must be capable of identifying these changes.

First, Some Important Safety Terminology

Safety terminology can appear complicated, but several concepts are fundamental.

Adverse Event — AE

An adverse event is an untoward medical occurrence in a participant and does not necessarily have a causal relationship with the investigational treatment.

For example, a participant receiving an investigational medicine develops a headache.

The headache is an adverse event regardless of whether the medicine actually caused it.

This distinction matters:

Temporal association is not automatically causation.

Serious Adverse Event — SAE

“Serious” has a specific regulatory meaning.

An event is generally considered serious when it results in outcomes such as:

• Death
• A life-threatening event
• Inpatient hospitalization or prolongation of existing hospitalization
• Persistent or significant disability/incapacity
• Congenital anomaly/birth defect

Certain medically important events may also be considered serious when medical judgment indicates that intervention is required to prevent one of these outcomes.

Importantly:

Seriousness is not the same as severity.

A severe headache may be extremely painful without meeting regulatory seriousness criteria.

Conversely, an event of relatively modest clinical intensity could be considered serious if it results in hospitalization.

Adverse Reaction

An adverse reaction introduces the concept of causality.

During clinical development, the assessment considers whether there is evidence supporting a reasonable possibility that the investigational product caused the event.

Causality assessment therefore becomes an important part of safety evaluation.

Unexpected Adverse Reaction

Expectedness asks a different question:

Is the nature or severity of this reaction consistent with the applicable reference safety information?

For investigational products, this assessment commonly involves the Investigator's Brochure and applicable reference safety information.

SUSAR

A Suspected Unexpected Serious Adverse Reaction (SUSAR) combines three important concepts:

Serious + Suspected relationship + Unexpected

These cases can trigger expedited regulatory reporting requirements.

ICH E2A established internationally harmonized terminology and standards for expedited reporting during clinical development.

But understanding these definitions is only the beginning of pharmacovigilance.

From the Patient to the Safety Database: What Happens After an SAE?

Imagine that a participant is admitted to hospital during a clinical trial.

What happens next?

The safety pathway may involve several interconnected steps:

Event occurs

↓

Site becomes aware

↓

Investigator assesses the event

↓

SAE information is reported to the sponsor according to protocol and applicable requirements

↓

Safety/PV team receives and processes the case

↓

Medical and regulatory assessment

↓

Seriousness, causality and expectedness are evaluated

↓

Follow-up information is requested where necessary

↓

Reporting obligations are determined

↓

Applicable regulatory authorities/investigators/ethics bodies receive required information

↓

The event contributes to cumulative safety evaluation

This entire pathway must function reliably.

A delay or breakdown at any point can have implications for participant protection and regulatory compliance.

The Investigator and Sponsor Have Different but Connected Responsibilities

Clinical trial safety depends upon clear communication between investigative sites and sponsors.

Investigators are positioned closest to participants.

They observe clinical events, evaluate participants, provide treatment and report relevant safety information.

Sponsors, meanwhile, have access to safety information across the broader development programme.

This gives the sponsor an important perspective that an individual investigator may not have.

A site may see one case.

The sponsor may see a pattern across 20 countries and multiple trials.

ICH E6(R3) explicitly places responsibility on sponsors for the ongoing safety evaluation of investigational products.

This is why effective pharmacovigilance requires both:

high-quality individual case information + cumulative analysis across the programme.

Not Every SAE Is Automatically an Expedited Safety Report

This is an important point.

A common misconception is:

SAE = immediate regulatory safety report.

That is not necessarily the case.

Regulatory requirements depend on factors such as seriousness, expectedness, causality and applicable jurisdictional requirements.

For example, under the U.S. IND framework, FDA requires sponsors to report certain serious and unexpected suspected adverse reactions. FDA emphasizes that evidence suggesting a causal relationship is necessary before an adverse event is classified as a suspected adverse reaction for this reporting purpose.

For reportable potential serious risks under the applicable IND requirements, the general reporting timeframe is no later than 15 calendar days, while qualifying unexpected fatal or life-threatening suspected adverse reactions are subject to a 7-calendar-day reporting timeframe.

This illustrates why medical assessment is so important.

Over-reporting every SAE as a suspected adverse reaction can create its own problem: large volumes of uninformative safety reports may obscure the signals that genuinely require attention.

Good pharmacovigilance is therefore not simply more reporting.

It is appropriate reporting supported by meaningful safety assessment.

Individual Cases Matter—but Patterns Matter More

Consider the following example.

Three participants experience myocardial infarction during a large cardiovascular trial.

Each case needs individual evaluation.

But the more important question may be:

Is the number of events unusual for this patient population?

That question cannot necessarily be answered by examining individual cases independently.

It may require aggregate evaluation comparing:

• Treatment groups
• Exposure
• Baseline disease risk
• Expected background incidence
• Timing
• Dose
• Concomitant medicines
• Biological plausibility

FDA's IND safety-reporting framework specifically recognizes circumstances where an aggregate analysis may provide evidence of a causal relationship—for example, when events common in the underlying study population occur more frequently in the investigational treatment group than in an appropriate comparator.

This illustrates an essential principle:

A safety signal may emerge from the relationship between cases—not from any single case alone.

Safety Reconciliation: When Clinical and Safety Databases Need to Agree

Clinical trials frequently maintain safety information in more than one system.

For example:

EDC: clinical trial data

PV database: individual safety case information

The same SAE may therefore exist in both environments.

But are the records consistent?

Does the event term match?

Are onset and resolution dates aligned?

Is seriousness recorded consistently?

Was follow-up information captured in both systems?

Is the participant identifier correct?

This is where SAE reconciliation becomes critical.

Clinical data management and pharmacovigilance teams need processes for identifying and resolving discrepancies between systems before study completion and database lock.

In increasingly digital clinical trials, integration between EDC and safety platforms can improve information flow—but technology does not remove the need for governance, validation and oversight.

Pharmacovigilance Is a Cross-Functional Responsibility

Although specialist PV teams manage many safety processes, patient safety cannot belong to one department.

Effective safety surveillance requires collaboration among:

Investigators

CRCs

CRAs

Clinical Project Managers

Medical Monitors

Pharmacovigilance Professionals

Data Managers

Medical Coders

Biostatisticians

Regulatory Teams

Quality Assurance

Consider a simple example.

A CRA identifies delayed SAE reporting during monitoring.

That is a clinical operations observation.

But it is also a pharmacovigilance issue.

It may also become:

• A training issue
• A protocol compliance issue
• A quality issue
• A regulatory issue

Clinical trial safety therefore depends on connected functions rather than departmental silos.

The Investigator's Brochure Is a Living Safety Document

The Investigator's Brochure (IB) is a critical source of information about an investigational product.

It brings together relevant clinical and nonclinical information required to support investigators' understanding and appropriate use of the investigational product.

But safety knowledge evolves.

Emerging information may therefore require updates to:

• The Investigator's Brochure
• Reference safety information
• Protocol
• Informed consent materials
• Risk mitigation procedures
• Monitoring requirements

ICH E6(R3) recognizes that the sponsor's review of emerging safety information may result in updates to the protocol, Investigator's Brochure, informed consent materials and related documents.

This demonstrates why pharmacovigilance should not be viewed as a downstream reporting function.

Safety findings can directly change how an ongoing clinical trial is conducted.

Annual Safety Reporting: Looking Beyond Individual Cases

Expedited reports address certain important emerging risks.

But sponsors also need to periodically evaluate the overall safety picture.

For investigational medicines, this is commonly supported through periodic aggregate reporting such as the Development Safety Update Report (DSUR) under the ICH E2F framework and applicable regional requirements.

Aggregate safety evaluation can consider:

• Cumulative exposure
• Serious adverse reactions
• Important identified and potential risks
• Relevant nonclinical findings
• Emerging safety signals
• Changes to reference safety information
• Overall benefit-risk considerations

This allows regulators and sponsors to consider the evolving safety profile as a whole.

The European Safety-Reporting Landscape

For clinical trials conducted under the EU Clinical Trials Regulation, several categories of safety information may require reporting.

These include:

SUSARs — reported through EudraVigilance.

Unexpected events affecting benefit-risk — reported through the Clinical Trials Information System (CTIS).

Urgent safety measures — actions required to protect participants when an unexpected event is likely to seriously affect the trial's benefit-risk balance.

Serious breaches — where relevant to participant safety/rights or reliability and robustness of trial data.

Annual safety reports — periodic safety updates concerning investigational medicinal products.

This demonstrates that modern safety oversight extends substantially beyond individual adverse-event case processing.

A Particularly Current Development in 2026

Safety reporting infrastructure itself continues to evolve.

In the United States, from 1 April 2026, applicable IND safety reports for serious and unexpected suspected adverse reactions are required to be submitted electronically to FDA's Adverse Event Monitoring System using E2B(R3) standards, subject to specified exemptions.

In Europe, EMA has also been developing the new CTIS Annual Safety Report module, with sponsor guidance and training released during 2026.

These developments illustrate a broader trend:

Pharmacovigilance is becoming increasingly digital, structured and interconnected with the wider clinical trial technology ecosystem.

But better systems alone do not guarantee better safety surveillance.

High-quality medical assessment and sound benefit-risk judgment remain indispensable.

What Happens When a New Safety Concern Emerges?

Imagine cumulative review suggests an unexpected hepatotoxicity risk.

The response should not stop with reporting the cases.

The sponsor may need to consider:

Does the protocol need additional liver-function monitoring?

Should eligibility criteria change?

Should dose interruption or stopping rules be modified?

Does the Investigator's Brochure need updating?

Do participants need new information through revised consent materials?

Do investigators need urgent communication?

Does the benefit-risk balance remain acceptable?

Are urgent safety measures necessary?

This is pharmacovigilance functioning as intended.

The purpose of safety data is not simply to populate a database.

It is to inform action.

Signal Detection During Clinical Development

A safety signal is information suggesting a new potentially causal association—or a new aspect of a known association—that warrants further investigation.

Signals can arise from:

• Individual cases
• Clusters of similar events
• Aggregate analyses
• Laboratory trends
• Clinical trial data
• Other studies
• Scientific literature
• Nonclinical findings
• Post-marketing information where the product is already marketed in another setting

Signal detection therefore requires both systematic processes and clinical judgment.

Not every statistical imbalance represents a genuine safety risk.

And not every important signal begins with a statistically significant finding.

Medical context matters.

Benefit-Risk Assessment Is Dynamic

Perhaps the most important concept in clinical trial pharmacovigilance is that benefit-risk is not static.

When a study begins, decisions are based on the information available at that time.

As new data emerge, the assessment may change.

The same adverse effect may also carry different implications depending on the disease.

For example, tolerance for significant toxicity may differ between:

• A treatment for a rapidly fatal cancer
• A therapy for a mild self-limiting condition

Safety therefore cannot be interpreted independently of:

disease severity + therapeutic benefit + alternative treatments + magnitude and reversibility of risk + patient population.

Pharmacovigilance ultimately supports this continuing benefit-risk judgment.

Quality in Pharmacovigilance: Timeliness and Accuracy Both Matter

Safety reporting is highly time-sensitive.

But speed without accuracy is not enough.

High-quality safety operations require:

• Clear reporting pathways
• Defined responsibilities
• Appropriate medical review
• Reliable safety databases
• Complete case documentation
• Follow-up processes
• Coding consistency
• Regulatory reporting controls
• SAE reconciliation
• Quality control
• Inspection-ready records

When clinical trials involve multiple countries, these processes become more complex because global standards must coexist with regional and national reporting requirements.

This is where experienced global safety oversight becomes particularly important.

The Future: Integrated Safety Surveillance

The future of clinical trial pharmacovigilance is likely to become increasingly integrated.

Rather than safety information sitting exclusively within a standalone database, modern clinical development can bring together information from:

EDC + Safety Database + Laboratory Data + ePRO + Wearables + Medical Literature + Other Clinical Studies + Real-World Data

Advanced analytics and artificial intelligence may help identify patterns across these large datasets.

But automation should support—not replace—medical judgment.

Algorithms can identify unusual patterns.

Experienced safety professionals must determine whether those patterns are clinically meaningful.

The future of PV therefore lies not in choosing between technology and human expertise.

It lies in combining them responsibly.

From Case Processing to Patient Protection

The distinction is fundamental.

A narrow view of pharmacovigilance asks:

“Was the SAE processed and reported on time?”

A mature safety organization asks:

“What does this event mean when considered alongside everything else we know about the product—and do we need to act?”

Both questions matter.

But only the second captures the full purpose of pharmacovigilance.

 

The Agile Clinical Trendz Perspective

At Agile Clinical Trendz, we believe pharmacovigilance should be integrated with clinical operations, medical oversight, data management, regulatory activities and quality systems throughout clinical development.

Effective safety management requires more than compliant case processing.

It requires:

Timely information.

Reliable systems.

Medical judgment.

Cross-functional communication.

Appropriate regulatory reporting.

Continuous aggregate evaluation.

And action when the emerging evidence requires it.

Because behind every adverse-event form is a participant.

And behind every safety database is a much larger responsibility:

To recognize emerging risk early enough to protect the people who make clinical research possible.

References

1. International Council for Harmonisation. ICH E2A: Clinical Safety Data Management—Definitions and Standards for Expedited Reporting. 1994.
2. International Council for Harmonisation. ICH E2F: Development Safety Update Report. 2010.
3. International Council for Harmonisation. ICH E6(R3): Guideline for Good Clinical Practice. 2025.
4. U.S. Food and Drug Administration. Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies: Guidance for Industry. December 2025.
5. U.S. Food and Drug Administration. Investigator Responsibilities—Safety Reporting for Investigational Drugs and Devices: Guidance for Industry. December 2025.
6. U.S. Food and Drug Administration. IND Application Reporting: IND Safety Reports. Updated 2026.
7. European Medicines Agency. Reporting Safety Information on Clinical Trials. Clinical Trials Regulation (EU) No 536/2014.
8. European Medicines Agency. Clinical Trials Information System: Annual Safety Report New Safety Module—Sponsor Guidance. 2026.